Rosaprostol | antiulcer drug | CAS#56695-66-0

MedKoo Cat#: 126442 | Name: Rosaprostol sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rosaprostol is an antiulcer drug.

Chemical Structure

Rosaprostol sodium

CAS#56695-66-0 (sodium)

Theoretical Analysis

MedKoo Cat#: 126442

Name: Rosaprostol sodium

CAS#: 56695-66-0 (sodium)

Chemical Formula: C18H33NaO3

Exact Mass: 320.2327

Molecular Weight: 320.45

Elemental Analysis: C, 67.47; H, 10.38; Na, 7.17; O, 14.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

56695-65-9 (free acid) 56695-66-0 (sodium)

Synonym

Rosaprostol sodium; Rosal; Ibi-C83;

IUPAC/Chemical Name

sodium 7-((1R,2S)-2-hexyl-5-hydroxycyclopentyl)heptanoate

InChi Key

ALNUHUMOGUVHIO-XXJNWDAFSA-M

InChi Code

InChI=1S/C18H34O3.Na/c1-2-3-4-7-10-15-13-14-17(19)16(15)11-8-5-6-9-12-18(20)21;/h15-17,19H,2-14H2,1H3,(H,20,21);/q;+1/p-1/t15-,16+,17?;/m0./s1

SMILES Code

[Na+].CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC([O-])=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 320.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Łukasik B, Perlikowska W, Żurawiński R, Mikołajczyk M. Synthesis of Enantiomerically Pure Stereomers of Rosaprostol. J Org Chem. 2015 Oct 2;80(19):9798-802. doi: 10.1021/acs.joc.5b01749. PubMed PMID: 26355965. 2: Segre G, Fiaschi AI, Bianchi E, Ciani D, Tedeschi S. Serum and urine kinetics of rosaprostol in volunteers. Arzneimittelforschung. 1988 Dec;38(12):1846-9. PubMed PMID: 3245860. 3: Perlikowska W, Żurawiński R, Mikołajczyk M. A new and expeditious synthesis of all enantiomerically pure stereoisomers of rosaprostol, an antiulcer drug. Beilstein J Org Chem. 2016 Oct 21;12:2234-2239. eCollection 2016. PubMed PMID: 27829932; PubMed Central PMCID: PMC5082602. 4: Tincani GP, Maniscalco G, Gunelli M, Ciarrocchi V. [Treatment of duodenal ulcer with rosaprostol in patients resistant to treatment with anti-H2]. Minerva Med. 1987 Jun 30;78(12):847-53. Italian. PubMed PMID: 2885786. 5: Di Murro R, Camarri E, Ciani D, Mariotti L, Nencioni C, Romagnoli AM. Effects of a synthetic prostanoid, rosaprostol, on the changes of gastric acidity and digestive disorders induced by NSAID. Int J Clin Pharmacol Res. 1988;8(5):345-51. PubMed PMID: 3068160. 6: Di Simone A, Riegler G, Esposito P, Ciani D. Short- and long-term treatment with rosaprostol of patients with gastritis. Int J Clin Pharmacol Res. 1988;8(3):217-21. PubMed PMID: 3403108. 7: Adami M, Scarpignato C, Signorini G, Coruzzi G, Bertaccini G. [Further observations of the inhibitory effect of the disodium salt of 9-hydroxy-8,12-trans-19,20-bis-norprostanoic acid (rosaprostol) on gastric secretion]. Farmaco Prat. 1984 Nov;39(11):409-16. Italian. PubMed PMID: 6526080. 8: Fumagalli R, Caponi R, Corsini A, Brambilla A, Palmira M, Bernini F, Valcavi U. Nonprotein sulfhydryls as possible components of the protective effect of rosaprostol on the rat gastric mucosa. Prostaglandins. 1985 Mar;29(3):467-74. PubMed PMID: 3858913. 9: Tanimori S, Kainuki T, Nakayama M. Synthesis of (+/-)-homosarkomycin and (+/-)-rosaprostol. Biosci Biotechnol Biochem. 1992 Nov;56(11):1807-9. PubMed PMID: 1369076. 10: Calcamuggi G, Babini G, Arduino C, Lanzio M, Anfossi G, Ciani D, Emanuelli G. A double blind randomized placebo-controlled study demonstrates the protective efficacy of rosaprostol on aspirin-induced gastrointestinal bleeding in man. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:789-92. PubMed PMID: 1825412. 11: Foschi D, Trabucchi E, Galeone M, Ferrante F, Toti GL, Castoldi L, Musazzi M, Centemero A, Montorsi W. Prostaglandin cytoprotection in man: effectiveness of rosaprostol. Int J Tissue React. 1988;10(1):53-7. PubMed PMID: 3397253. 12: Cataldo MG, Sallì L, Scalici G, D'Aiuto A, Bongiorno A, Salerno L. [Cytoprotective effect of rosaprostol during treatment with non-steroidal anti-inflammatory agents in arthrorheumatic pathologies]. Minerva Dietol Gastroenterol. 1989 Jul-Sep;35(3):191-4. Italian. PubMed PMID: 2601868. 13: Benfenati E, Fanelli R, Chiabrando C, Valcavi U, Bosone E, Farina P. Mass spectrometric identification of urinary and plasma metabolites of 9-hydroxy-19,20-bis-nor-prostanoic acid (rosaprostol). Prostaglandins. 1988 May;35(5):665-84. PubMed PMID: 3399677. 14: Ciprandi G, Scordamaglia A, Ruffoni S, Pizzorno G, Ferrini O, Canonica GW. Terfenadine (single or associated) treatment of adverse reactions to foods. Allergol Immunopathol (Madr). 1987 Jul-Aug;15(4):201-3. PubMed PMID: 3120557. 15: Foschi D, Ferrante F, Callioni F, Bastagli A, Rovati V. The effects of 9-hydroxy-19,20-bis-norprostanoic acid on mucus, acid and gastrin secretion in duodenal ulcer patients. Prostaglandins Leukot Med. 1984 Aug;15(2):147-52. PubMed PMID: 6593741. 16: Canonica GW, Ciprandi G, Scordamaglia A, Ruffoni S, Pizzorno G, Caria M, Cheli R. Cytoprotective drugs: a new perspective in the treatment of adverse reactions to foods. Ann Allergy. 1988 Jun;60(6):541-5. PubMed PMID: 2968061. 17: Trost BM, Pinkerton AB. A three-component coupling approach to cyclopentanoids. J Org Chem. 2001 Nov 16;66(23):7714-22. PubMed PMID: 11701026. 18: Takahashi K, Niidome T, Akaike A, Kihara T, Sugimoto H. Amyloid precursor protein promotes endoplasmic reticulum stress-induced cell death via C/EBP homologous protein-mediated pathway. J Neurochem. 2009 Jun;109(5):1324-37. doi: 10.1111/j.1471-4159.2009.06067.x. Epub 2009 Mar 26. PubMed PMID: 19476545. 19: Scordamaglia A, Ciprandi G, Indiveri F, Canonica GW. The effect of aging on host defences. Implications for therapy. Drugs Aging. 1991 Jul-Aug;1(4):303-16. Review. PubMed PMID: 1794022. 20: Tanahashi H, Yoshioka K. RNA interference silencing of DRAL affects processing of amyloid precursor protein. Neurosci Lett. 2008 Jul 18;439(3):293-7. doi: 10.1016/j.neulet.2008.05.039. Epub 2008 May 16. PubMed PMID: 18534756.